289 related articles for article (PubMed ID: 24324749)
1. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
Cao W; Zhao C; Shen C; Wang Y
PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749
[TBL] [Abstract][Full Text] [Related]
2. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease.
Kim YS; Jung ES; Hur W; Bae SH; Choi JY; Song MJ; Kim CW; Jo SH; Lee CD; Lee YS; Choi SW; Yang JM; Jang JW; Kim SG; Jung SW; Kim HK; Chae HB; Yoon SK
Clin Mol Hepatol; 2013 Jun; 19(2):120-30. PubMed ID: 23837136
[TBL] [Abstract][Full Text] [Related]
5. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
[TBL] [Abstract][Full Text] [Related]
6. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ
Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618
[TBL] [Abstract][Full Text] [Related]
8. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
[TBL] [Abstract][Full Text] [Related]
12. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
13. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.
Eguchi A; Iwasa M; Yamada M; Tamai Y; Shigefuku R; Hasegawa H; Hirokawa Y; Hayashi A; Okuno K; Matsushita Y; Nakatsuka T; Enooku K; Sakaguchi K; Kobayashi Y; Yamaguchi T; Watanabe M; Takei Y; Nakagawa H
Hepatol Commun; 2022 Aug; 6(8):1987-1999. PubMed ID: 35485207
[TBL] [Abstract][Full Text] [Related]
14. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
[TBL] [Abstract][Full Text] [Related]
15. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.
Wu XX; Zheng KI; Boursier J; Chan WK; Yilmaz Y; Romero-Gómez M; El Kassas M; Targher G; Byrne CD; Huang ZM; Zheng MH
EClinicalMedicine; 2021 Nov; 41():101145. PubMed ID: 34646997
[TBL] [Abstract][Full Text] [Related]
16. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population.
Hasegawa Y; Kim SR; Hatae T; Ohta M; Fujinami A; Sugimoto K; Kim KI; Imoto S; Tohyama M; Kim SK; Ikura Y; Kudo M
Dig Dis; 2015 Oct; 33(6):715-20. PubMed ID: 26488474
[TBL] [Abstract][Full Text] [Related]
19. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
Sorbi D; Boynton J; Lindor KD
Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
[TBL] [Abstract][Full Text] [Related]
20. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
